Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603181 | 1.00 | CYP2D6 (0.46) | CYP2D6MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6598452 | 1.00 | CYP2D6 (0.46) | CYP2D6MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7241761 | 0.90 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL7246774 | 0.90 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL9137386 | 0.90 | CYP2D6 (0.40) | CYP2D6MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9149395 | 0.90 | CYP2D6 (0.40) | CYP2D6MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9137378 | 0.90 | CYP2D6 (0.40) | CYP2D6MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1944494 | 0.85 | SLC6A3 (0.45) | SLC6A3 | |
| SCHEMBL14605737 | 0.85 | SLC6A3 (0.45) | SLC6A3 | |
| SCHEMBL12538344 | 0.85 | SLC6A3 (0.45) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286965-B1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | SYNTHON BV (NL) | 2004-01-14 | — | — | EP | claimed |
| EP-1286965-A1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | Synthon B.V. (NL) | 2003-03-05 | — | — | EP | claimed |
| US-20020099219-A1 | Piperidine compounds and process for providing the same | SYNTHON BV (NL) | 2002-07-25 | — | — | US | claimed |
| WO-2001085689-A1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | SYNTHON B.V. (NL) | 2001-11-15 | — | — | WO | claimed |
| EP-1286965-B1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | SYNTHON BV (NL) | 2004-01-14 | — | — | EP | disclosed |
| US-20030187269-A1 | Novel process | SMITHKLINE BEECHAM PLC (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1286965-A1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | Synthon B.V. (NL) | 2003-03-05 | — | — | EP | disclosed |
| US-20020099219-A1 | Piperidine compounds and process for providing the same | SYNTHON BV (NL) | 2002-07-25 | — | — | US | disclosed |
| WO-2001085689-A1 | PIPERIDINE COMPOUNDS AND PROCESS FOR PROVIDING SUCH | SYNTHON B.V. (NL) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099219-A1 | Piperidine compounds and process for providing the same | HTR6, TPH1, CYP2D6 | CYP2D6 3/4885MEN1 3657/4885CYP1A2 29/4885 |
| US-20030187269-A1 | Novel process | TPO, KCNH3, HCCS | CYP2D6 1818/4885MEN1 149/4885CYP1A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.